I feel for holders of MSB ... the FDA can be a fickle beast.We,...

I feel for holders of MSB ... the FDA can be a fickle beast.

We, on the other hand, have our FDA clearance for Conneqt Pulse( I recall a " we love the FDA " banner " in April ) , and are now working towards mass production and product launch in 2 months time. Yes, we have worked through some shareholder capital to get this point, but it pales into insignificance against the capital invested by the share holders of MSB.

And yet, our SP is half what it was prior to the trading halt for the FDA approval ( 0.335 vs 0.165 ). It beggars belief really
No wonder CDX Management see .30 as a more reasonable SP, as per the SP attributed to Integrous Communications share allocation last night.

;
So, as we approach the launch of Conneqt Pulse, a reminder of the dynamics of the market we are chasing :







This report talks to market developments & product innovations introduced by Omron Healthcare being a " great success ".
Rather than be worried by this, I see it as an indicator that the market is ready to embrace & adopt change.
That is, if Conneqt Pulse delivers the goods, the market will react accordingly.

Omron EVOLV .... a great success.
The innovation was all around the " all in one" feature - no attached cuff, and wireless link back to your smartphone.
No Vascular biometrics, no Central Blood Pressure ... a snazzier looking monitor that talks to your phone, but no innovation on what actually counts, your health & biometric readings. Conneqt Pulse will of course talk to your smartphone, apps etc.






So, CONNEQT PULSE, about to launch into a $4.5B USD market with an FDA approved device.
CardieX, about to IPO on the NASDAQ to ensure they have the funding to support the launch and achieve market traction.
CardieX Market Cap - USD$17M , Really ....

And virtually no market movement in the week just gone.
And we ask why Craig wants his essentially US based business listed on the NASDAQ , he says tongue in cheek.

All IMO.
Looking forward to next weeks webinar.